Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.48 |
| ▸ | SGK1 | O00141 | 3/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438406 | 0.83 | AXL (0.50) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL13306699 | 0.83 | AXL (0.50) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL29438408 | 0.83 | AXL (0.50) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL30731289 | 0.80 | AXL (0.45) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL22554109 | 0.80 | AXL (0.45) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL20319065 | 0.80 | AXL (0.45) | AXLCAMKK2SGK1DYRK1ACLK1 | |
| SCHEMBL29564788 | 0.80 | AXL (0.45) | AXLCAMKK2SGK1ITK | |
| SCHEMBL2671287 | 0.80 | AXL (0.45) | AXLCAMKK2SGK1ITK | |
| SCHEMBL2181151 | 0.78 | BTK (0.45) | AXLCAMKK2SGK1BRD4MAPK1 | |
| SCHEMBL13387062 | 0.78 | AXL (0.44) | AXLCAMKK2SGK1DYRK1ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | FELICITEX THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | FELICITEX THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3558321-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119039-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119039-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | DYRK1A, DYRK1B, DYRK2 | AXL 875/4885CAMKK2 69/4885SGK1 64/4885 |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | DYRK1A, DYRK1B, DYRK2 | AXL 875/4885CAMKK2 69/4885SGK1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.